Back

Effects of SGLT2 inhibitors on hyperuricemia in patients with chronic heart failure with reduced ejection fraction.

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Heart failure with reduced ejection fraction (HFrEF) (2) Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Nabil Naser

Polyclinic Dr. Nabil - Faculty of Medicine University of Sarajevo, Sarajevo (Bosnia and Herzegovina)

2 More presentations in this session

Presentation thumbnail
Iron deficiency and anemia in heart failure with mildly reduced ejection fraction and their impact on prognosis and right ventricular-pulmonary artery coupling
Doctor Y. Fukunaga (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Platelet counts and prognosis in heart failure with mildly reduced ejection fraction: results from a large-scale registry
Mr J. Dudda (Mannheim, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure with reduced ejection fraction (HFrEF) (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Comparing treatment strategies for heart failure: a real-world analysis of adding ARNI or SGLT2i to older GDMT
thumbnail
Congress Presentation
Low levels of irisin predicted worsening kidney function in dapagliflozin-treated patients with chronic heart failure and concomitant type 2 diabetes mellitus
thumbnail
Congress Presentation
Hyperuricemia as an indicator of severe congestion and increased disease burden in heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources